# ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients

> **NCT01464827** · PHASE2 · COMPLETED · sponsor: **AbbVie (prior sponsor, Abbott)** · enrollment: 580 (actual)

## Conditions studied

- Chronic Hepatitis C
- Hepatitis C (HCV)
- Hepatitis C Genotype 1

## Interventions

- **DRUG:** ABT-450
- **DRUG:** ABT-333
- **DRUG:** ABT-267
- **DRUG:** Ribavirin
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT01464827
- **Lead sponsor:** AbbVie (prior sponsor, Abbott)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2013-03
- **Final completion:** 2013-09
- **Target enrollment:** 580 (ACTUAL)
- **Last updated:** 2015-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01464827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01464827, "ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01464827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*